Study Details

Back to Search Results

Study of an Investigational Drug, ASP3026, in Patients with Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01284192

Astellas Study ID

The unique identification code given by the study sponsor.

A3026-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Advanced/Metastatic Cancer, Lymphoma, Other

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Dec 2010 - Mar 2016

Masking

None (Open Label)

Enrollment number

46

A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP3026 in Subjects with Advanced Malignancies

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Study of an Investigational Drug, ASP3026, in Patients with Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US160

Orange, United States, 92868

Site US2688

Detroit, United States, 48201

Site US184

Sacramento, United States, 95817

Site US11

Chicago, United States, 60637

Site US2492

Houston, United States, 77030

Site US1905

San Antonio, United States, 78229

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo